SCHEMBL4069117

SCHEMBL4069117

COc1cccc(-c2ncc(CN(Cc3cccc(CNC(=O)c4c(Cl)cncc4Cl)c3)C3CCCc4cccnc43)[nH]2)c1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CXCR4 P61073 6/20 0.40
CCR5 P51681 3/20 0.39
CYP3A4 P08684 2/20 0.37
CYP2D6 P10635 2/20 0.37
MAPT P10636 2/20 0.37
AURKA O14965 1/20 0.37
ROCK1 Q13464 3/20 0.36
PRKACA P17612 1/20 0.36
GRK5 P34947 1/20 0.36
PRKX P51817 1/20 0.36
PRKCQ Q04759 1/20 0.36
ROCK2 O75116 3/20 0.36
SLC6A9 P48067 1/20 0.36
KMT2A Q03164 1/20 0.36
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35
THRB P10828 1/20 0.35
DGAT2 Q96PD7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4062721 0.96 CXCR4 (0.39) CXCR4CCR5CYP3A4CYP2D6SLC6A9
SCHEMBL4067849 0.95 CXCR4 (0.41) CXCR4CCR5CYP3A4CYP2D6SLC6A9
SCHEMBL13964834 0.92 CXCR4 (0.45) CXCR4CYP3A4CYP2D6ROCK2
SCHEMBL4067958 0.89 CXCR4 (0.41) CXCR4CCR5CYP3A4CYP2D6SLC6A9
SCHEMBL4071964 0.89 CXCR4 (0.42) CXCR4CCR5CYP3A4CYP2D6
SCHEMBL4069541 0.88 CXCR4 (0.43) CXCR4CCR5CYP3A4CYP2D6MAPT
SCHEMBL4067393 0.85 CXCR4 (0.44) CXCR4CYP3A4CYP2D6
SCHEMBL4072372 0.84 CXCR4 (0.43) CXCR4CCR5CYP3A4CYP2D6ROCK1
SCHEMBL4067843 0.84 CXCR4 (0.42) CXCR4CCR5CYP3A4CYP2D6MAPT
SCHEMBL7172861 0.83 CXCR4 (0.43) CXCR4CYP3A4CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080090846-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS GENZYME CORPORATION 2008-04-17 US claimed
US-7312234-B2 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2007-12-25 US claimed
EP-1317443-B1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC (CA) 2009-01-14 EP disclosed
US-20080090846-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS GENZYME CORPORATION 2008-04-17 US disclosed
US-7312234-B2 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2007-12-25 US disclosed
US-20050026942-A1 Chemokine receptor binding heterocyclic compounds ANORMED (CA) 2005-02-03 US disclosed
US-6835731-B2 Viricides; antiinflammatory agents; antiallergens; antiarthritic agents ANORMED, INC. (CA) 2004-12-28 US disclosed
EP-1317443-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2003-06-11 EP disclosed
US-20020147192-A1 Chemokine receptor binding heterocyclic compounds GENZYME CORPORATION 2002-10-10 US disclosed
WO-2002022599-A2 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS ANORMED INC. (CA) 2002-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147192-A1 Chemokine receptor binding heterocyclic compounds CCR2, CXCR3, ACKR3 CXCR4 9/4885CCR5 5/4885CYP3A4 1925/4885
US-20080090846-A1 CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS CCR2, CXCR3, ACKR3 CXCR4 9/4885CCR5 5/4885CYP3A4 1925/4885
US-20050026942-A1 Chemokine receptor binding heterocyclic compounds CCR2, CXCR3, ACKR3 CXCR4 9/4885CCR5 5/4885CYP3A4 1925/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.